On January 4, 2022 Nuvalent, Inc. (Nasdaq: NUVL), a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, reported that James Porter, Ph.D., Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 11:15 a.m. ET (Press release, Nuvalent, JAN 4, 2022, View Source [SID1234598157]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast will be available in the investor section of the company’s website at www.nuvalent.com, and archived for 30 days following the presentation.

On January 4, 2022 Caris Life Sciences (Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, reported that the Company will present at the 40th Annual J.P. Morgan Healthcare Conference, which is being held virtually on January 10-13, 2022 (Press release, Caris Life Sciences, JAN 4, 2022, View Source [SID1234598154]). Caris will be presenting via the live conference webcast on January 11, at 11:30 a.m. ET, and will provide an overview of the business and discuss recent corporate achievements that position the organization to further extend its leadership position in the market.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Caris will be represented by David D. Halbert, Chairman and Chief Executive Officer, Brian J. Brille, Vice Chairman, David Spetzler, MS, MBA, Ph.D., President and Chief Scientific Officer, Mike Weinstein, Executive Vice President and Chief Financial Officer and Brian Lamon, Ph.D., Chief Business Officer, Head of BioPharma Business Development.

On January 4, 2021 Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, reported that Joseph Oliveto, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright BIOCONNECT Virtual Conference being held on January 10-13, 2022 (Press release, Milestone Pharmaceuticals, JAN 4, 2022, View Source [SID1234598152]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The prerecorded fireside chat will become available on Monday, January 10, 2022 at 7:00am ET and can be accessed in the News & Events section of Milestone’s website at www.milestonepharma.com. An archived replay of the fireside chat will be available on the same website 90 days following the presentation.

On January 4, 2021 Perrigo Company plc (NYSE; TASE: PRGO), reported that President and CEO, Murray S. Kessler is scheduled to present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 3:45 PM (EST) (Press release, Perrigo Company, JAN 4, 2022, View Source [SID1234598151]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interested parties can access the presentation webcast on the Perrigo website at View Source

On January 4, 2022 Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, reported that Marc N. Casper, chairman, president and chief executive officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 8:15 a.m. (EST) (Press release, Thermo Fisher Scientific, JAN 4, 2022, View Source [SID1234598150]). Among other topics, Mr. Casper will provide the company’s current perspective on its business and expectations for future financial performance.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com.